J&J’s Tapentadol Raises Competitive Bar in Pain Market
Executive Summary
Johnson & Johnson's newly approved acute pain drug tapentadol will likely face more market competition from tramadol generics than the drug the company compared it to in Phase III studies - oxycodone, analysts say
You may also be interested in...
J&J's Phase III Tapentadol Beats Oxycodone Side Effects
Outlined studies include foot-surgery pain.
J&J Projects Nine NME Filings By 2010, Keeping Pace With Previous Years
With the Jan. 22 filing of the pain medication tapentadol, Johnson & Johnson made the first of the nine new molecular entity filings it expects to make through 2010
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.